Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Correction: Brolucizumab—early real-world experience: BREW study

The Original Article was published on 24 July 2020

Correction to: Eye

Since online publication of this article, the authors became aware of two errors in the text of the manuscript:

  1. 1.

    Page 1 Paragraph 1, an incorrect approval date was inserted. The correct sentence is provided below:

    Brolucizumab (Beovu, Novartis, Basel, Switzerland) is the newest anti-vascular endothelial growth factor (anti-VEGF) drug. lt was approved for the treatment of neovascular age-related macular degeneration (nAMD) by the US-FDA on October 7, 2019, followed by the European Commission’s approval for use in the European Union on February 13, 2020.

  2. 2.

    Page 2 Paragraph 1, an incorrect percentage was provided. The correct sentence is provided below:

Pigment epithelial detachment (PED) was present in 31 eyes (73.8%) at baseline and resolved in 2 eyes (6.4%), was reduced in 13 eyes (41.9%\, and did not show any change in 16 eyes (51.6%) (Fig. 1).

The authors apologise for any inconvenience caused.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Ashish Sharma.

Additional information

The original article can be found online at

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sharma, A., Kumar, N., Parachuri, N. et al. Correction: Brolucizumab—early real-world experience: BREW study. Eye 35, 1286 (2021).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links